Intrinsic resistance to KRAS inhibition: Interfering with interferon
Cancer Cell · 2026-11 · 44 (11) · 2123-2125
DOI: 10.1016/j.ccell.2026.10.001 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancer Cell, 2026-11. Verfasst von Borja Miguel-López und 1 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), 37007 Salamanca, Spain. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, Interferons. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), 37007 Salamanca, Spain.
- Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), 37007 Salamanca, Spain. Electronic address: mdrosten@usal.es.
Zitieren
APA
Miguel-López, B., & Drosten, M. (2026). Intrinsic resistance to KRAS inhibition: Interfering with interferon. Cancer Cell, 44(11), 2123-2125. https://doi.org/10.1016/j.ccell.2026.10.001
Vancouver
Miguel-López B, Drosten M. Intrinsic resistance to KRAS inhibition: Interfering with interferon. Cancer Cell. 2026;44(11):2123-2125. doi:10.1016/j.ccell.2026.10.001
BibTeX
@article{MiguelLpez2026,
author = {Miguel-López, Borja and Drosten, Matthias},
title = {Intrinsic resistance to KRAS inhibition: Interfering with interferon},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {11},
pages = {2123--2125},
doi = {10.1016/j.ccell.2026.10.001}
}
EUVIMED